Prognostic significance of TRAIL death receptors in Middle Eastern colorectal carcinomas and their correlation to oncogenic KRAS alterations

Molecular Cancer

Volumn 9, Issue , 2010, Pages

  Bavi, Prashant ^a   Prabhakaran, Sarita E ^a   Abubaker, Jehad ^a   Qadri, Zeeshan ^a   George, Thara ^a   Al Sanea, Nasser ^a   Abduljabbar, Alaa ^a   Ashari, Luai H ^a   Alhomoud, Samar ^a   Al Dayel, Fouad ^a   Hussain, Azhar R ^a   Uddin, Shahab ^a   Al Kuraya, Khawla S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DEATH RECEPTOR 4; DEATH RECEPTOR 5; ISOPROTEIN; K RAS PROTEIN; K RAS PROTEIN 4A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG; DEATH RECEPTOR;

ADENOCARCINOMA; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COLON; COLORECTAL CARCINOMA; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC CORRELATION; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MIDDLE EAST; ONCOGENE K RAS; OVERALL SURVIVAL; PHENOTYPE; PROGNOSIS; TISSUE MICROARRAY; COLORECTAL TUMOR; GENETICS; METABOLISM; ONCOGENE RAS; PATHOLOGY; SURVIVAL;

COLORECTAL NEOPLASMS; GENES, RAS; HUMANS; MIDDLE EAST; PROGNOSIS; RECEPTORS, DEATH DOMAIN; SURVIVAL ANALYSIS;

EID: 77955930419     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-9-203     Document Type: Article

References (60)

1. Al-Eid HS AS. Cancer Incidence Report Saudi Arabia 1999-200. 2004, King Faisal Specialist Hospital and Research Centre, May 2004.
2. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008, 44:946-953. 10.1016/j.ejca.2008.03.006, 18396036.
3. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000, 21:485-495. 10.1093/carcin/21.3.485, 10688869.
4. Nagata S. Apoptosis by death factor. Cell 1997, 88:355-365. 10.1016/S0092-8674(00)81874-7, 9039262.
5. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005, 55:178-194. 10.3322/canjclin.55.3.178, 15890640.
6. Qiao L, Wong BC. Targeting apoptosis as an approach for gastrointestinal cancer therapy. Drug Resist Updat 2009, 12:55-64. 10.1016/j.drup.2009.02.002, 19278896.
7. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 2003, 10:66-75. 10.1038/sj.cdd.4401187, 12655296.
8. Pukac L, Kanakaraj P, Humphreys R, Alderson R, Bloom M, Sung C, Riccobene T, Johnson R, Fiscella M, Mahoney A, et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005, 92:1430-1441. 10.1038/sj.bjc.6602487, 2361994, 15846298.
9. Martin JH, Potthoff A, Ledig S, Cornberg M, Jandl O, Manns MP, Kubicka S, Flemming P, Athmann C, Beil W, Wagner S. Effect of H. pylori on the expression of TRAIL, FasL and their receptor subtypes in human gastric epithelial cells and their role in apoptosis. Helicobacter 2004, 9:371-386. 10.1111/j.1083-4389.2004.00269.x, 15361075.
10. Kuraoka K, Matsumura S, Sanada Y, Nakachi K, Imai K, Eguchi H, Matsusaki K, Oue N, Nakayama H, Yasui W. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan. Oncol Rep 2005, 14:465-470.
11. Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277:815-818. 10.1126/science.277.5327.815, 9242610.
12. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277:818-821. 10.1126/science.277.5327.818, 9242611.
13. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000, 2:241-243. 10.1038/35008667, 10783243.
14. Zhang XD, Franco A, Myers K, Gray C, Nguyen T, Hersey P. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 1999, 59:2747-2753.
15. Pai SI, Wu GS, Ozoren N, Wu L, Jen J, Sidransky D, El-Deiry WS. Rare loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer Res 1998, 58:3513-3518.
16. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res 1999, 59:5683-5686.
17. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, Kim SY, Lee JH, Han SY, Park JY, Oh RR, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene 2001, 20:399-403. 10.1038/sj.onc.1204103, 11313970.
18. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, Park JY, Lee JH, Lee SK, Lee SN, Jung SS, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res 2001, 61:4942-4946.
19. Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004, 5:501-512. 10.1016/S1535-6108(04)00113-8, 15144957.
20. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2004, 64:3922-3927. 10.1158/0008-5472.CAN-03-2219, 15173003.
21. Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, Pintzas A. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 2005, 280:22856-22867. 10.1074/jbc.M412483200, 15757891.
22. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, Shen Q, O'Hagan R, Pantginis J, Zhou H, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400:468-472. 10.1038/22788, 10440378.
23. Li W, Zhu T, Guan KL. Transformation potential of Ras isoforms correlates with activation of phosphatidylinositol 3-kinase but not ERK. J Biol Chem 2004, 279:37398-37406. 10.1074/jbc.M405730200, 15210703.
24. Plattner R, Gupta S, Khosravi-Far R, Sato KY, Perucho M, Der CJ, Stanbridge EJ. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene 1999, 18:1807-1817. 10.1038/sj.onc.1202482, 10086335.
25. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822. 10.1038/sj.onc.1202367, 9989833.
26. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, Moller P, Lehnert T. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002, 8:3734-3740.
27. Koornstra JJ, Jalving M, Rijcken FE, Westra J, Zwart N, Hollema H, de Vries EG, Hofstra RW, Plukker JT, de Jong S, Kleibeuker JH. Expression of tumour necrosis factor-related apoptosis-inducing ligand death receptors in sporadic and hereditary colorectal tumours: potential targets for apoptosis induction. European Journal of Cancer 2005, 41:1195-1202. 10.1016/j.ejca.2005.02.018, 15911244.
28. Granci V, Bibeau F, Kramar A, Boissiere-Michot F, Thezenas S, Thirion A, Gongora C, Martineau P, Del Rio M, Ychou M. Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas. Eur J Cancer 2008, 44:2312-2318. 10.1016/j.ejca.2008.06.042, 18755584.
29. Ullenhag GJ, Mukherjee A, Watson NF, Al-Attar AH, Scholefield JH, Durrant LG. Overexpression of FLIPL is an independent marker of poor prognosis in colorectal cancer patients. Clin Cancer Res 2007, 13:5070-5075. 10.1158/1078-0432.CCR-06-2547, 17785559.
30. van Geelen CM, Westra JL, de Vries EG, Boersma-van Ek W, Zwart N, Hollema H, Boezen HM, Mulder NH, Plukker JT, de Jong S, et al. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients. J Clin Oncol 2006, 24:4998-5004. 10.1200/JCO.2006.06.8809, 17075118.
31. Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, de Jong S. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003, 200:327-335. 10.1002/path.1364, 12845629.
32. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995, 3:673-682. 10.1016/1074-7613(95)90057-8, 8777713.
33. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996, 271:12687-12690. 10.1074/jbc.271.22.12687, 8663110.
34. Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, Paraskeva C, MacFarlane M. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer 2005, 92:736-742. 10.1038/sj.bjc.6602387, 2361885, 15685228.
35. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195. 10.1038/40657, 9217161.
36. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304. 10.1038/40901, 9230442.
37. Wirth T, Kuhnel F, Fleischmann-Mundt B, Woller N, Djojosubroto M, Rudolph KL, Manns M, Zender L, Kubicka S. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res 2005, 65:7393-7402. 10.1158/0008-5472.CAN-04-3664, 16103092.
38. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002, 21:2283-2294. 10.1038/sj.onc.1205258, 11948412.
39. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, Liu CG, Croce CM, Condorelli G. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene 2008, 27:3845-3855. 10.1038/onc.2008.6, 18246122.
40. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001, 93:1062-1074. 10.1093/jnci/93.14.1062, 11459867.
41. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003, 112:481-486. 171400, 12925686.
42. Oikonomou E, Kosmidou V, Katseli A, Kothonidis K, Mourtzoukou D, Kontogeorgos G, Andera L, Zografos G, Pintzas A. TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors. Int J Cancer 2009, 125:2127-2135. 10.1002/ijc.24613, 19637313.
43. Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, et al. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma. J Pathol 2009, 219:435-445. 10.1002/path.2625, 19824059.
44. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995. 10.1158/0008-5472.CAN-06-0191, 16618717.
45. Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 2009, 69:1851-1857. 10.1158/0008-5472.CAN-08-2466, 19223544.
46. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465. 10.1038/nrc1097, 12778136.
47. Capon DJ, Seeburg PH, McGrath JP, Hayflick JS, Edman U, Levinson AD, Goeddel DV. Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 1983, 304:507-513. 10.1038/304507a0, 6308467.
48. Welman A, Burger MM, Hagmann J. Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation. Oncogene 2000, 19:4582-4591. 10.1038/sj.onc.1203818, 11030147.
49. Plowman SJ, Arends MJ, Brownstein DG, Luo F, Devenney PS, Rose L, Ritchie AM, Berry RL, Harrison DJ, Hooper ML, Patek CE. The K-Ras 4A isoform promotes apoptosis but does not affect either lifespan or spontaneous tumor incidence in aging mice. Exp Cell Res 2006, 312:16-26. 10.1016/j.yexcr.2005.10.004, 16271715.
50. Patek CE, Arends MJ, Rose L, Luo F, Walker M, Devenney PS, Berry RL, Lawrence NJ, Ridgway RA, Sansom OJ, Hooper ML. The pro-apoptotic K-Ras 4A proto-oncoprotein does not affect tumorigenesis in the ApcMin/+ mouse small intestine. BMC Gastroenterol 2008, 8:24. 10.1186/1471-230X-8-24, 2442095, 18554389.
51. Bavi P, Jehan Z, Atizado V, Al-Dossari H, Al-Dayel F, Tulbah A, Amr SS, Sheikh SS, Ezzat A, El-Solh H, et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:1708-1718. 10.1158/1055-9965.EPI-05-0972, 16985034.
52. Sanlioglu AD, Dirice E, Elpek O, Korcum AF, Balci MK, Omer A, Griffith TS, Sanlioglu S. High levels of endogenous tumor necrosis factor-related apoptosis-inducing ligand expression correlate with increased cell death in human pancreas. Pancreas 2008, 36:385-393. 10.1097/MPA.0b013e318158a4e5, 18437085.
53. Tomek S, Koestler W, Horak P, Grunt T, Brodowicz T, Pribill I, Halaschek J, Haller G, Wiltschke C, Zielinski CC, Krainer M. Trail-induced apoptosis and interaction with cytotoxic agents in soft tissue sarcoma cell lines. Eur J Cancer 2003, 39:1318-1329. 10.1016/S0959-8049(03)00227-2, 12763223.
54. McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985, 109:716-721.
55. Uddin S, Siraj AK, Al-Rasheed M, Ahmed M, Bu R, Myers JN, Al-Nuaim A, Al-Sobhi S, Al-Dayel F, Bavi P, et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J Clin Endocrinol Metab 2008, 93:4088-4097. 10.1210/jc.2008-0503, 18682509.
56. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004, 10:7252-7259. 10.1158/1078-0432.CCR-04-0713, 15534099.
57. McCarthy MM, Sznol M, DiVito KA, Camp RL, Rimm DL, Kluger HM. Evaluating the expression and prognostic value of TRAIL-R1 and TRAIL-R2 in breast cancer. Clin Cancer Res 2005, 11:5188-5194. 10.1158/1078-0432.CCR-05-0158, 16033835.
58. Uddin S, Ahmed M, Bavi P, El-Sayed R, Al-Sanea N, AbdulJabbar A, Ashari LH, Alhomoud S, Al-Dayel F, Hussain AR, Al-Kuraya KS. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Cancer Res 2008, 68:3379-3388. 10.1158/0008-5472.CAN-07-6109, 18451165.
59. Shapira M, Ben-Izhak O, Bishara B, Futerman B, Minkov I, Krausz MM, Pagano M, Hershko DD. Alterations in the expression of the cell cycle regulatory protein cyclin kinase subunit 1 in colorectal carcinoma. Cancer 2004, 100:1615-1621. 10.1002/cncr.20172, 15073847.
60. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, Abduljabbar A, Ashari LH, Alhomoud S, Al-Dayel F, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008, 27:3539-3545. 10.1038/sj.onc.1211013, 18193083.